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Continued-Warfarin
Versus Heparin-Bridging
Therapy During Pacemaker
and Deﬁbrillator SurgeryIn patients receiving warfarin due to high risk of
thromboembolic events, current guidelines recom-
mend bridging therapy with heparin or low molec-
ular weight heparin (LMWH) during surgery for
cardiac pacemakers or implantable cardioverter-
deﬁbrillators (1). Bridging therapy is associated
with increased costs due to increased need for hos-
pitalization and the high price of LMWH (2). The
recent randomized controlled BRUISE CONTROL
(Bridge or Continue Coumadin for Device Surgery
Randomized Controlled Trial; NCT00800137) of 681
patients undergoing nonemergency device surgery
found that patients receiving continued-warfarintherapy experienced signiﬁcantly fewer clinically
signiﬁcant hematomas than those receiving heparin-
bridging therapy (3). In this economic evaluation,
we compared treatment with warfarin to bridging
therapy with heparin.
From the perspective of the Canadian health-
care system, this study sought to assess the cost
effectiveness of continued-warfarin versus heparin-
bridging therapy in pacemaker or deﬁbrillator
surgery using data from the recent single-blind ran-
domized controlled trial (4). We collected resource
use for the initial hospitalization, including antico-
agulant usage, hospitalization for intravenous hepa-
rin administration (17% of heparin-bridging arm),
laboratory tests, and extensions of hospitalization
due to complications; and at ﬁnal follow-up to assess
repeat hospitalizations, emergency room visits, and
management of complications. Appropriate Canadian
unit costs were obtained for all resource use collected
and estimated for 2012 to 2013 (5). The primary
outcome measure was the incremental cost or cost
savings per hematoma avoided with appropriate
assessment of the uncertainty around the estimates of
costs, outcomes, and incremental cost-effectiveness
ratios (4). The effect of a range of factors on the
costs within the 2 treatment arms was explored
through sensitivity analyses.
The overall cost of continued-warfarin therapy was
dramatically lower than heparin-bridging therapy
($218 vs. $2,041; p < 0.001), primarily due to lower
costs for medication ($11.57  $0.64 vs. $353.91 
$15.09) and hospitalizations ($41.72  $37.81 vs.
$1,114.60  $164.90). There were more clinically
signiﬁcant hematomas within the bridging-heparin
group compared with continued-warfarin group
(54 vs. 12, respectively), resulting in a trend for
increased hematoma costs per patient in the heparin-
bridging group ($511.89  $199.26 vs. $118.89 
$69.50; p ¼ 0.060).
Continued-warfarin therapy had fewer clinically
signiﬁcant hematomas compared with heparin-
bridging therapy (3.6% vs. 16.6%; p < 0.001). As
continued-warfarin therapy was also less costly, it
was dominant. In all replications of the non-
parametric bootstrap, continued-warfarin therapy
remained dominant indicating little uncertainty
in the results. Continued-warfarin therapy remained
the dominant treatment strategy in all analyses
(Table 1).
In conclusion, continued-warfarin therapy was
found to be cost effective compared with bridging-
heparin therapy in patients at high risk of throm-
boembolic events undergoing device surgery, with a
cost savings of approximately $1,800 per patient
TABLE 1 Results of Cost-Effectiveness Analysis
Total Costs Clinically Signiﬁcant Hematoma
ICERWarfarin Bridging p Value Warfarin Bridging p Value
Base case $217.62
(n ¼ 335)
$2,040.68
(n ¼ 326)
<0.001 3.6% 16.6% <0.001 Dominant
Physician performing surgery
EP staff physician $227.84
(n ¼ 313)
$2,035.43
(n ¼ 305)
<0.001 3.5% 16.1% <0.001 Dominant
Staff surgeon $87.70
(n ¼ 17)
$2,760.24
(n ¼ 15)
0.005 5.9% 20.0% 0.242 Dominant
Cardiologist $19.12
(n ¼ 5)
$508.33
(n ¼ 6)
0.117 0.0% 33.3% 0.186 Dominant
Fellow/resident present
Yes $194.41
(n ¼ 166)
$2,370.46
(n ¼ 153)
<0.001 3.0% 15.0% <0.001 Dominant
No $240.41
(n ¼ 169)
$1,749.02
(n ¼ 173)
<0.001 4.1% 17.9% <0.001 Dominant
Restricted to those receiving LMWH only $217.62
(n ¼ 335)
$799.69
(n ¼ 258)
<0.001 3.6% 16.7% <0.001 Dominant
Sensitivity analysis
Including post-procedural hospitalization $2,444.04
(n ¼ 335)
$4,141.17
(n ¼ 326)
<0.001 3.6% 16.6% <0.001 Dominant
100% increase in unit cost of hospitalizations $388.33
(n ¼ 326)
$3,631.91
(n ¼ 335)
<0.001 3.6% 16.6% <0.001 Dominant
100% increase in unit cost of physician visits $222.47
(n ¼ 326)
$2,059.14
(n ¼ 335)
<0.001 3.6% 16.6% <0.001 Dominant
Costs are in Canadian dollars. One patient was missing information regarding body mass index, and 3 patients were missing data regarding duration of surgery.
EP ¼ electrophysiology; ICER ¼ incremental cost-effectiveness ratio; LMWH ¼ low molecular weight heparin.
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958treated. Heparin-bridging therapy was associated
with increased incidence of hematomas and conse-
quent hospital stays, as well as higher medication
costs. The ﬁndings were consistent regardless of
the format of heparin used as the bridging therapy
and across a range of subgroups. The extent of
savings may be mitigated by increasing the degree
to which heparin-bridging could be transferred
into the community in the 17% of patients who
had hospital based heparin, as well as differential
drug costs in different health delivery systems.
Continued-warfarin therapy results in better out-
comes at a lower cost than heparin-bridging therapy
in patients requiring anticoagulation therapy who
are undergoing surgery for either a pacemaker or
deﬁbrillator.Doug Coyle, PhD
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Accessed November 1, 2014.A Mechanistic Explanation
for the Minimal Impact of
Renal Denervation on 24-h
Ambulatory Blood Pressure
in SIMPLICITY HTN-3Explanations for the lack of signiﬁcant lowering of
24-h ambulatory blood pressure following renal
denervation in SYMPLICITY HTN-3 (Renal Denerva-
tion in Patients With Uncontrolled Hypertension)
have been offered, including the unanticipated fall
in ambulatory BP in the sham operated group,
perhaps as a result of a Hawthorne effect or placebo
effect (1). Alternatively, the recognized individual
variation in renal nerve anatomy may have led to
inadequate renal denervation in a large proportion of
patients, because it is not yet practical or routine to
conﬁrm successful renal denervation following the
clinical procedure (1,2). I would like to offer an
alternative explanation, with clinical implications.
The majority of patients enrolled in SYMPLICITY
HTN-3 were obese, deﬁned as body mass index (BMI)
>30 kg/m2. The mean BMI in the renal denervation
group was 34.2  6.5 kg/m2. Although sympathetic
nerve activity, including renal sympathetic nerve
activity, is known to be elevated in human obesity
(3,4), sympathetic activity is not greater in obese
patients with hypertension compared with those
without hypertension. That is, renal sympathetic
activation may not play a mechanistic role in the
development of hypertension associated with com-
mon human obesity. This contrasts markedly with
the situation in lean humans. In lean patients with
hypertension, renal sympathetic nerve activity is
markedly increased compared with lean normoten-
sive humans, in whom renal sympathetic nerve
activity is not elevated (5). Renal sympathetic nerve
activation may play a central role in the develop-
ment of hypertension in lean, but not obese, pa-
tients. I wonder if a post-hoc analysis (with all the
pitfalls of such an analysis) of SYMPLICITY HTN-3
might be illuminating. When stratiﬁed by BMI, isthere a lean cohort that particularly beneﬁts from
renal denervation?*Holly R. Middlekauff, MD
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Medicine (Cardiology)
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tension 2007;50:862–8.REPLY: A Mechanistic Explanation forthe Minimal Impact of Renal Denervation
on 24-h Ambulatory Blood Pressure in
SIMPLICITY HTN-3
We appreciate Dr. Middlekauff’s interest in the re-
sults of SYMPLICITY HTN-3 (Renal Denervation in
Patients With Uncontrolled Hypertension) and her
thoughtful letter suggesting an alternative explana-
tion for the failure to demonstrate a beneﬁt of renal
denervation based on ambulatory blood pressure
monitoring. The research cited by Esler et al. (1)
and Lambert et al. (2) provides interesting evi-
dence that the role of sympathetic nervous system
hyperactivity in the etiology of essential hyperten-
sion is different between obese and lean patients with
hypertension. However, the clinical implications of
the difference in sympathetic nerve ﬁring between
obese and lean hypertensive patients are unknown.
We undertook a post-hoc analysis of the blood
pressure–lowering effect of renal denervation com-
pared with sham control according tertiles of body
mass index (BMI). No differences between renal de-
nervation and sham were found. Further exploration
of results in patients with a normal BMI (#27 kg/m2)
also revealed no difference between denervation and
